John Murphy: Generics, Biosimilars, and U.S. Policy
Description
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with John Murphy, President and CEO of the Association for Accessible Medicines (AAM), to discuss how U.S. purchasing dynamics and thin margins drive shortages, the evolving biosimilar landscape amid insurer vertical integration, the Inflation Reduction Act (IRA)’s ripple effects on plan risk and rebates, Most Favored Nation (MFN) policy proposals, and what it will take to reshore capacity while preserving competition and patient access.
Key Topics:
-
Generic Pricing Pressures: Purchaser consolidation, sterile injectables, margin squeeze, and exits.
-
Drug Shortage Economics: Quality investments, underpriced redundancy, lessons from saline disruptions.
-
Biosimilar Market Dynamics: Private-label payer programs, rebate tactics, chilling pipeline investment.
-
Inflation Reduction Act (IRA) and Coverage: Part D risk shift to plans, negotiation uncertainty, and Medicare access delays.
-
Tariffs and Reshoring: API onshoring realities, carve-outs to avoid shortages, resilient capacity building.
Opinions expressed are those of the speakers.
See omnystudio.com/listener for privacy information.
United States
